Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

By sjmartinez • December 20, 2024

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM, Tian H, Watts JM. Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm. Br J Haematol. 2024 Dec 19. doi: 10.1111/bjh.19944. Epub ahead of print. PMID: 39701584.

Tags: acute myeloid leukaemia, blast‐phase myeloproliferative neoplasm, Hematology/Oncology, IDH1 mutation, myeloproliferative neoplasms, Publications

Impact of clonal hematopoiesis of indeterminate potential on treatment outcomes in multiple myeloma patients undergoing CAR-T cell therapy

Carlson SG, Puliafito BR, Kawai K, Senaratne TN, Lee TD, Lin T, Timmerman J, Larson SM. Impact of clonal hematopoiesis of indeterminate potential on treatment[...]

Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up

Owen RG, McCarthy H, D'Sa S, Thomas SK, Tournilhac O, Forconi F, Kersten MJ, Zinzani PL, Iyengar S, Kothari J, Minnema MC, Kastritis E, Cheson[...]

Exploring Features of the Parasport Environment Associated With Quality Participation

Gee CM, Evans MB, Sinden AR, Shirazipour CH, Martin Ginis KA, Latimer-Cheung AE. Exploring Features of the Parasport Environment Associated With Quality Participation. Adapt Phys[...]